Virtus Biotech ETF BBP
101.53 USD -3.85 (-3.65%)
Nov 5, 2026, 1:07 PM EST
101.54 Day range 105.46
73.55 52-week range 110.05
- YTD
- +27.04%
- 1 year
- +36.91%
- Market cap
- 41.86M
- YTD return
- +27.04%
- 1-year return
- +36.91%
- Volume
- 9.89K
- Avg volume
- 12.27K
- Open
- 105.46
- Previous close
- 105.38
- Day's range
- 101.54 – 105.46
- 52-week range
- 73.55 – 110.05
2Y +38.14 (+58.74%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 63.72
- 200-day average
- 60.18
About Virtus Biotech ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
News
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels 
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 
BBP: The Biotech ETF That Filters For FDA-Approved Drugs 
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug 
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check 
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use 
Why Is ImmunityBio Stock Soaring On Friday?
Your note
Sign in to keep a note on BBP — it syncs with the Stock Master app.